The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/201345
EDITORIAL ADVISORY BOARD John Baldoni Chair, Leadership Development Practice N2growth Heather Erickson President and CEO Life Sciences Foundation Mary Rose Keller VP Clinical Operations Sangart Greg MacMichael, Ph.D. Global Head of Biologics Process R&D; Novartis John Orloff, M.D. Senior VP, CMO, Global Development Novartis Pharma AG Rafik Bishara, Ph.D. Chair, Pharmaceutical Cold Chain Interest Group, PDA Jeffrey Evans, Ph.D. Life Science Entrepreneur Norman Klein Principal, Core Results Jerold Martin Chairman Bio-Process Systems Alliance (BPSA) Mark Pykett, Ph.D. President and CEO Navidea Biopharmaceuticals Tina Morris, Ph.D. VP, Biologics and Biotechnology USP Division of Documentary Standards John Reynders, Ph.D. Chief Information Officer Moderna Therapeutics Bernard Munos Founder, InnoThink Center for Research in Biomedical Innovation James Robinson VP, Vaccine & Biologics Technical Operations, Merck Mike Myatt Leadership Adviser, N2growth Mark Snyder, Ph.D. Former Associate Director, Purification Process Development Bayer HealthCare Timothy Krupa Tim Freeman President, TSK Clinical Development Director of Operations at Freeman Technology and Past Chair of the Process Analytical Technology Focus Group of AAPS John LaMattina, Ph.D. Senior Partner, PureTech Ventures Ron Cohen, M.D. Laura Hales, Ph.D. President and CEO Eric Langer Founder, The Isis Group Acorda Therapeutics , Inc. President and Managing Partner BioPlan Associates Fred Hassan Laurie Cooke Chairman of the Board CEO Lynn Johnson Langer, Ph.D. Healthcare Businesswomen's Association (HBA) Bausch + Lomb Director, Enterprise and Regulatory Affairs Program John Hubbard, Ph.D. Alan Eisenberg Center for Biotechnology Education Senior VP & Worldwide Head Executive VP, Emerging Johns Hopkins University of Development Operations, Pfizer Companies and Bus. Dev. Biotechnology Industry Organization (BIO) Craig Lipset Maik Jornitz Head of Clinical Innovation, Founder, BioProcess Resources, LLC Barry Eisenstein, M.D. Worldwide Research & Development Immediate Past Chair PDA Senior VP, Scientific Affairs Pfizer Cubist Pharmaceuticals Mitchell Katz, Ph.D. Exec. Dir. of Medical Research Operations Purdue Pharma, L.P. G. Steven Burrill CEO & Founder, Burrill & Company Carol Nacy, Ph.D. CEO, Sequella, Inc. Leslie Williams Founder, President, and CEO ImmusanT Sesha Neervannan, Ph.D. VP Pharmaceutical Development Allergan Kevin O'Donnell Senior Partner, Exelsius Cold Chain Mgt. Consultancy U.S., Chair Int. Air Transport Assoc. Time & Temp. Task Force Ann Willmoth General Manager Blue Standard Consulting Save The Date | 03.12.14 The CMO Leadership Awards Reception & Ceremony Join us at the W Hotel, New York City, to celebrate award recipients, network with industry leaders, and make new business contacts. For more information, email cmoawards@lifescienceleader.com. PRESENTED BY : RESEARCH CONDUCTED BY : SPONSORED BY : A LIFE SCIENCE CONNEC T BRAND ASK THE BOARD Have a response to our experts' answers or a question of your own? Send us an email to atb@lifescienceconnect.com. Q: What life sciences industry leader have you met who truly impressed you, and what could other leaders learn from this person? Peter Green is now retired, after a 30-year career working for several leading pharma companies including GSK and Pfizer. I met him at Pfizer where he was a senior scientist with a Ph.D. in biochemistry. He was an exceptional leader who set clear expectations, followed through on priorities, and put his people first. He said his proudest accomplishment was the many great people that he had the opportunity to help develop. I saw this firsthand at Pfizer. Those on Peter's team were engaged and motivated. Peter set high expectations, and he provided the support employees needed to do well. Peter's advice to scientists entering management is timeless. "Don't be tempted to interfere with the scientists. You are now a manager; learn how to do this well, and enable the scientists to do their job well." John Baldoni John Baldoni is an internationally recognized leadership development consultant, executive coach, author, and speaker. John teaches men and women to achieve positive results by focusing on communication, influence, motivation, and supervision. 8 LifeScienceLeader.com Q: What advice would you have for pharma/bio execs about preparing for a TV interview? Focus on three to four key messages. Avoid industry-specific terms that a general audience might not know. TV interviews generally last only a few minutes, so make sure to logically work in your key messages during the first one to two questions. Rehearse working in your key messages regardless of the question. Memorize a few key statistics, anecdotes, or other details that support your positions. Tailor your messages to the audience. Watch a few interviews by the reporter you'll be working with to understand their style. If you get a random question, don't ignore it, but move quickly to bring the conversation back to your key messages. Ron Cohen, M.D. Cohen is president, CEO, and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for spinal cord injury, multiple sclerosis, and other nervous system disorders. November 2013 Q: What role should insurance companies play in the drug discovery process, and how best should this be facilitated? Make no mistake about it, payers LOVE competition! Companies go into intense negotiations over pricing when they have to outbid another company for a major contract. Before starting any drug discovery program, you must have the end game in mind — i.e. will the insurance companies be willing to pay for it? How will the drug that emanates from this program effectively compete with existing or anticipated therapies when it is approved in 12 years? In areas where no therapy exists, this is a no-brainer. A new discovery approach fits this category. But let's say your idea is for a new approach to treat breast cancer. There are a number of compounds on the market to treat this disease and dozens more in development. How will your new approach, if successful, compare to what will be established therapy? John LaMattina, Ph.D. LaMattina is the former senior VP at Pfizer Inc. and the president of Pfizer Global Research and Development. In this role, he oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe, and Asia.